Personalized Anti-Inflammatory Systems

Publication ID: 24-11857607_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Personalized Anti-Inflammatory Systems,” Published Technical Disclosure No. 24-11857607_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857607_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,607.

Summary of the Inventive Concept

The present invention relates to the integration of anti-inflammatory peptides with advanced technologies such as AI, IoT, blockchain, and biodegradable nanomaterials to create personalized treatment systems for inflammatory diseases.

Background and Problem Solved

The original patent disclosed anti-inflammatory peptides and compositions for treating dermal related inflammatory diseases. However, the peptides' efficacy and safety were limited by their administration routes, dosages, and individual variability in response. The present invention addresses these limitations by incorporating machine learning, IoT, blockchain, and advanced biomaterials to create a more effective and personalized treatment approach.

Detailed Description of the Inventive Concept

The inventive concept comprises a system that integrates anti-inflammatory peptides with AI-powered analytics to predict optimal treatment outcomes based on a subject's genetic profile and medical history. The system utilizes wearable IoT devices to track the subject's physiological response to the peptide and blockchain technology to securely store and analyze the subject's medical data. Additionally, the system incorporates biodegradable nanomaterials to enhance the peptide's bioavailability and stability. The inventive concept also includes a method for generating personalized anti-inflammatory peptides using AI-driven molecular design and simulation tools, which are optimized for specific inflammatory disorders and produced using advanced biomanufacturing techniques.

Novelty and Inventive Step

The present invention's novelty lies in the synergistic combination of anti-inflammatory peptides with advanced technologies to create a personalized treatment system. The inventive step is the integration of these distinct technologies to address the limitations of the original patent and provide a more effective and targeted treatment approach.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include the use of different AI algorithms, IoT devices, and biomaterials. Variations of the system could include the integration of additional technologies such as gene editing or stem cell therapy to further enhance the treatment's efficacy and personalization.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the treatment of inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease. The system's ability to provide personalized treatment approaches could revolutionize the field of inflammatory disease treatment and improve patient outcomes.

CPC Classifications

Section	Class	Group
A	A61	A61K38/45
A	A23	A23L33/18
A	A61	A61K8/64
A	A61	A61Q19/00
C	C07	C07K7/08
C	C07	C07K14/4703
C	C12	C12N9/0069
C	C12	C12N9/0083
C	C12	C12Y113/11
C	C12	C12Y114/99001
C	C12	C12Y207/07049
A	A23	A23V2002/00
A	A61	A61K38/00
Y	Y02	Y02A50/30

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biotechnology and pharmaceutical sciences, specifically peptide-based anti-inflammatory treatments with a focus on personalized medicine, molecular design, and advanced drug delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biotechnology, pharmaceutical sciences, or biomedical engineering, possessing expertise in peptide engineering, AI-driven molecular design, nanomaterial development, and personalized medical technologies

Obviousness Rationale

A PHOSITA would recognize that integrating advanced technologies with existing anti-inflammatory peptide treatments represents a predictable evolution of personalized medicine. The combination of AI, IoT, and nanomaterials with known peptide therapies would be considered an obvious approach to enhancing treatment precision and efficacy. The source patent's foundational anti-inflammatory peptide technology provides a clear starting point for technological augmentation through well-established interdisciplinary approaches.

Obvious Combinations & Variations

Source Patent Element

Anti-inflammatory peptide with specific administration routes and dosage ranges

PTD Variation

AI-powered personalized dosage optimization and administration strategy based on genetic profiling

Obviousness Reasoning

Predictable application of machine learning to personalize existing treatment protocols, representing a known technique in precision medicine

Source Patent Element

Peptide composition for treating dermal inflammatory conditions

PTD Variation

Integration of biodegradable nanomaterials to enhance peptide bioavailability and stability

Obviousness Reasoning

Well-established nanotechnology approach for improving drug delivery, representing a finite and predictable solution to enhancing peptide effectiveness

Source Patent Element

Method of administering anti-inflammatory peptides

PTD Variation

Real-time monitoring of physiological responses using IoT devices and blockchain data management

Obviousness Reasoning

Logical extension of existing medical monitoring technologies to improve treatment tracking and personalization

Source Patent Element

Peptide composition for inflammatory disease treatment

PTD Variation

AI-driven molecular design tools for generating optimized peptide variants

Obviousness Reasoning

Applying computational design techniques to refine existing peptide structures, representing a standard approach in biotechnological research

Source Patent Element

Anti-inflammatory peptide with defined administration parameters

PTD Variation

Blockchain-secured personalized medical data integration for predictive inflammation management

Obviousness Reasoning

Predictable application of secure data technologies to enhance medical treatment personalization and risk assessment

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the instant publication would be considered obvious to a person having ordinary skill in the art at the time of invention, when viewed in light of US Patent 11857607. The combination of known technologies and predictable design choices renders the claimed innovations obvious, thus establishing this publication as valid prior art that would anticipate or render obvious subsequent patent claims in the domain of personalized anti-inflammatory treatment systems.

Original Patent Information

Patent Number	US 11,857,607
Title	Anti-inflammatory peptides and composition comprising the same
Assignee(s)	GemVax & KAEL Co., Ltd.